UK: UK Cancer Survival Rates Still Trailing European Peers

Last Updated: 12 February 2018
Article by Matthew Thaxter

Most people will have been impacted by cancer in some way – whether themselves, a family member, a loved one or an acquaintance. Stories about the causes of cancer and examples of exciting new breakthrough treatments feature regularly in media headlines. However, one issue more than any others attracts attention, and that's evidence of inequalities in patient outcomes. Last week's World Cancer Day, on 4th February, coincided with the publication of the CONCORD-3 report, comparing the outcomes for cancer patients from 73 different countries over the period 2000-2014.1 This week's blog reflects on some of the developments in the UK given the results of this ground breaking research suggests that the UK continues to lag behind many other comparable European countries.

About the Concord research programme

CONCORD is an international scientific collaboration, led by the London School of Hygiene & Tropical Medicine, designed to monitor trends in the survival of cancer patients world-wide and enable a comparative evaluation of the effectiveness of health systems in providing cancer care. The research is also used to contribute to the evidence base for national and global policies on cancer control. The third report, was published in the Lancet in January 2018, and is based on an analysis of the clinical records of over 37 million patients from 71 countries, diagnosed with one of 18 types of cancer (2000-2014).2

The CONCORD-3 study, found that although cancer survival has generally increased, even for some of the more deadly cancers such as liver and lung, survival trends vary widely. Moreover, there are wide and persistent disparities between countries, particularly for some childhood cancers. The research considers that this is largely due to the availability and quality of diagnostic and treatment services.

UK performance in the CONCORD-3 analysis

In the UK, the results from the latest survey show that overall cancer survival is improving, with several cancers showing substantial increases in five-year survival, including breast (80% to 86%), prostate (82% to 89%), rectum (55% to 63%) and colon (52% to 60%); reflecting better cancer management. However, adults with cancer continue to have lower five-year survival than in many other comparable countries for several common cancers:

  • lung cancer is the deadliest type of cancer in the UK, claiming a total of 35,486 lives in 2015. Based on five-year survival rates, the UK ranks 21st out of 27 other European Union (EU) countries
  • with 16,067 deaths in 2015, colorectal cancer has the second highest mortality in the UK. For colon cancer and for cancer of the rectum, the UK ranked 17th and 12th respectively in its five-year survival rates
  • prostate cancer is now the third most common cause of cancer death in the UK (11,819 deaths in 2015), overtaking breast cancer with 11,442 deaths in 2015.3 The study data, ranks the UK in 16th and 14th places respectively, for five year survival from prostate and breast cancers
  • the UK also ranks 14th for blood cancer, 20th for pancreatic cancer, 21st for brain cancer and 24th out of 27 for stomach cancer.4

Improving future survival rates

While this analysis of UK performance does raise some important questions, the governments in all four UK countries have recognised this and over the past decade and a half have published numerous national strategies and actions plans. For example, in England the first National Cancer Plan was published in in 20005 followed by the Cancer Reform Strategy in 2007.6 Over the past decade specific funding has also been provided for investment in innovative diagnostic and treatments.

The most recent strategy was published in July 2015 by an Independent Cancer Taskforce - Achieving world-class cancer outcomes: a strategy for England 2015-2020. And in 2016 the National Cancer Transformation Board published a wide range of specific steps designed to increase prevention, speed up diagnosis, improve the experience of patients and help people living with and beyond the disease.8 Indeed, the Department of Health and Social Care has said that cancer remains a priority, noting that survival rates are at a record high, with 7,000 more people surviving cancer compared with three years ago. Indeed, across all main cancers, five year survival have improved in the past decade (see Figure 1).9

Figure 1 – Five-year survival rates (%) for UK for analysed cancers

Source: CONCORD -3, 2018

*NOTE: ALL=Acute lymphoblastic leukaemia

Despite the numerous initiatives and strategies aimed at improving the UK's cancer survival rates including improving access to earlier diagnosis, improving access to surgery and radiotherapy, and tackling health inequalities through targeting primary prevention and public health; research, like the CONCORD-3 study, continue to show inequalities in cancer outcomes in comparison with other countries.

Uptake of national cancer screening programmes

A key initiative is the availability of national screening programmes and the UK currently offers three screening programmes for bowel, breast and cervical cancer. However recent reports show that these programmes are not being fully utilised. For example, the percentage of women taking up invitations from breast cancer screening was at the lowest level in a decade in 2017, dropping to 71 per cent of women.10 Furthermore, additional data from 2016-17 showed that over 1.2 million women in the UK (25 per cent of the eligible population) did not take up their invitation for cervical screening.11 These reports are worrying, and they suggest that women may not be receiving the information or support needed to make the correct decision for them.

If the UK is to improve its survival rates from these cancers in particular, then encouraging greater uptake of available screening programmes needs to be a priority. Indeed as we showed in a report 'Working differently to provide early diagnosis: Improving access to diagnostics' , earlier diagnosis is the most important factor in improving cancer outcomes. This is particularly evident when we consider breast cancer as an example – the five-year survival rate for breast cancer diagnosed at stage I is 90 per cent, but this drops drastically to just 13 per cent when diagnosed at stage IV. The need for earlier diagnosis has clearly been recognised and the NHS has announced plans to employ more cancer specialists to speed up diagnoses as part of Health Education England's new Cancer Workforce Plan. Ultimately, while the UK has made progress in improving its cancer survival rates in recent years, one fact remains, it still lags behind many comparable European nations, suggesting a more radical refresh of its approach may be necessary.

Footnotes

1 http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)33326-3/fulltext?elsca1=tlpr

2 http://csg.lshtm.ac.uk/wp-content/uploads/2018/01/CONCORD-3-FAQ-26-Jan-2018.pdf

3 http://www.bbc.co.uk/news/health-42890405

4 http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)33326-3/fulltext?elsca1=tlpr

5 http://webarchive.nationalarchives.gov.uk/+/http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4009609

6 http://webarchive.nationalarchives.gov.uk/20130104165259/http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_081006

7 http://www.cancerresearchuk.org/about-us/cancer-strategy-in-england

8 https://www.england.nhs.uk/cancer/strategy/

9 http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)33326-3/fulltext?elsca1=tlpr

10 http://www.independent.co.uk/news/health/breast-cancer-screening-tests-lowest-level-decade-women-health-take-up-nhs-a8187156.html

11 https://www.nhs.uk/news/cancer/one-three-women-dont-attend-cervical-screening-because-embarrassment/

12 https://www2.deloitte.com/uk/en/pages/life-sciences-and-healthcare/articles/working-differently-to-provide-early-diagnosis.html

13 https://www.kingsfund.org.uk/sites/default/files/How-to-improve-cancer-survival-Explaining-England-poor-rates-Kings-Fund-June-2011.pdf

14 https://www.gov.uk/government/news/more-cancer-specialists-to-be-employed-by-the-nhs

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions